Hitesh Gandhi

Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: SABINA Findings From Europe and North America

Jennifer K Quint, Sofie Arnetorp, Janwillem Kocks et al. · The Journal of Allergy and Clinical Immunology In Practice · 2022 · 79 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure

Kevin R. Murphy, Bradley E. Chipps, David A. Beuther et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 73 citations

Medicine, Preventive Medicine, Health Assessment +8

The Asthma Impairment and Risk Questionnaire (AIRQ) Control Level Predicts Future Risk of Asthma Exacerbations

David A. Beuther, Kevin R. Murphy, Robert S. Zeiger et al. · The Journal of Allergy and Clinical Immunology In Practice · 2022 · 26 citations

Pharmacy, Preventive Medicine, Epidemiology +11

Real-world patterns and implications of short-acting β2-agonist use in patients with asthma in the United States

Njira Lugogo, Ileen Gilbert, Joseph Tkacz et al. · Annals of Allergy Asthma & Immunology · 2021 · 25 citations

Pharmacy, Internal Medicine, Pharmacotherapy +15

The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population

Michael Pollack, Hitesh Gandhi, Joseph Tkacz et al. · Journal of Managed Care & Specialty Pharmacy · 2022 · 18 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17